The market for targeted anticancer drugs for EGFR, which is prescribed to patients with non-small cell lung cancer with specific mutation findings, set a record for sales last year. The benefit of Tagrisso, a third-generation drug that is effective in the treatment of resistance to existing drugs, has been listed.

According to IQVIA on the 2nd, the domestic epithelial growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) market in Korea was ₩152 billion, up 15.0% from the previous year. Compared to ₩57.6 billion in 2016, the sales volume increased 2.6 times over the past four years.

'Four types of EGFR-TKI, including Iressa (Gefitinib), Tarceva (Erlotinib HCl), Giotrif (